U.S. ResidentsGLIVEC HISTORY AND TIMELINE
GLIVEC has been approved in the EU and the US for the treatment of1:
- Adult and pediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) CML for whom bone marrow transplantation is not considered as the first line of treatment
- Adult and pediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis
- Adult patients with KIT (CD 117)-positive unresectable and/or metastatic malignant GIST
- The adjuvant treatment of adult patients who are at significant risk of relapse following resection of KIT (CD 117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment
- Adult patients with newly diagnosed Ph+ acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy
- Adult patients with relapsed or refractory Ph+ ALL as monotherapy
- Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements
- Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRa rearrangement
- Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery
Learn more at GIST Alliance, a
program designed to help healthcare
program designed to help healthcare
professionals
optimize outcomes
in KIT+ GIST patients
Review the NCCN
and ESMO
Guidelines
